Neutralizing Tumor Necrosis Factor Activity Leads to Remission in PatientsWith Refractory Noninfectious Posterior Uveitis

Open Access
Publisher Website
Google Scholar
Abstract
Noninfectious posterior segment intraocular inflammation (PSII) encompassesa group of immune-mediated conditions that are variably characterized by relapsing-remittinginflammation of the choroid, retina, ciliary body, and vitreous.1 Traditionallyclassified as intermediate, posterior, and panuveitis, these conditions predominantlyaffect young and middle-aged people and are a significant cause of visualimpairment.2 The mainstay of therapy for PSIIis corticosteroids, with the addition of immunosuppressive agents such ascyclosporine, azathioprine, tacrolimus, and mycophenolate mofetil if required.3,4 With this approach, ocular inflammationcan be controlled in most patients, but many remain refractory to therapyor develop a toxic reaction to the drug, indicating the need to develop moreeffective and safer therapies.

This publication has 12 references indexed in Scilit: